Alterations in Intestinal Mucosal Barrier Visualized by Confocal Laser Endomicroscopy in Liver Cirrhosis: a Pilot Trial (AMBIC)

Sponsor
Dr.med. Monica Rusticeanu (Other)
Overall Status
Terminated
CT.gov ID
NCT03878563
Collaborator
University Hospital Inselspital, Berne (Other), University of Bern (Other)
26
2
19
13
0.7

Study Details

Study Description

Brief Summary

Clinical trial with medical devices. A diagnostic trial conducted to find a better (less invasive) procedure for predicting the onset of spontaneous bacterial peritonitis(SBP), which is a complication of liver cirrhosis with ascites.The current recommendation for primary prophylaxis of SBP include a low protein content of the ascitic fluid or a gastrointestinal bleeding. This trial will use the CLE (confocal laser endomicroscopy) technic in order to quantify the intestinal permeability in patients with liver cirrhosis and correlate this to the onset of spontaneous bacterial peritonitis.We aim to evaluate a new diagnostic tool (the confocal laser endoscopy(CLE) technique -cellvizio- in the setting of endoscopy and defining parameters that are altered in cirrhotic patients of different severity and being at risk of developing a SBP (spontaneous bacterial peritonitis).The parameters assessed by confocal laser endomicroscopy will be correlated with the protein content in ascitic fluid and the patient will be monitored for time to occurrence of spontaneous bacterial peritonitis.

Defining a correlation between the quantified loss of intestinal integrity and i) total protein concentration in the ascitic fluid and ii) stadium of liver disease (Child class A, B or C)

Condition or Disease Intervention/Treatment Phase
  • Device: Cellvisio 100 Series (fibered confocal microscopic system)

Study Design

Study Type:
Observational
Actual Enrollment :
26 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Alterations in Intestinal Mucosal Barrier Visualized by Confocal Laser Endomicroscopy in Liver Cirrhosis: a Pilot Trial
Actual Study Start Date :
Nov 20, 2017
Actual Primary Completion Date :
Jun 20, 2019
Actual Study Completion Date :
Jun 20, 2019

Arms and Interventions

Arm Intervention/Treatment
ascites with/without SBP

Cirrhosis with ascites and existing SBP or prior SBP

Device: Cellvisio 100 Series (fibered confocal microscopic system)
This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope. An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD.

ascites and decreased protein concentrati

Cirrhosis with ascites and decreased protein concentration <1,5 g/d

Device: Cellvisio 100 Series (fibered confocal microscopic system)
This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope. An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD.

ascites and normal protein concentration

Liver cirrhosis witha scites and protein concentration >1,5 g/d

Device: Cellvisio 100 Series (fibered confocal microscopic system)
This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope. An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD.

Liver cirrhosis without ascites

Patients with liver corrhosis without ascites

Device: Cellvisio 100 Series (fibered confocal microscopic system)
This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope. An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD.

Healthy controls without liver cirrhosis or other pathology

Healthy pacients (without chronic disease) undergoing screening coloscopy or gastroscopy

Device: Cellvisio 100 Series (fibered confocal microscopic system)
This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope. An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD.

Outcome Measures

Primary Outcome Measures

  1. occurrence of spontaneous bacterial peritonitis at 12 months [24 months]

    The parameters assessed by confocal laser endomicroscopy will be correlated with the protein content in ascitic fluid and the patient will be monitored for occurrence of spontaneous bacterial peritonitis for the next 12 months.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Inclusion Criteria:

Adult individual (>18yo) with liver cirrhosis of any cause and healthy controls undergoing elective endoscopy

Exclusion Criteria:
  • Patients younger than < 18, older than 80 years

  • Pregnant or breastfeeding women

  • Known allergy to fluorescein.

  • Cardiac disease

  • Asthma bronchiale

  • Patients with inability or unwillingness to provide blood samples or samples of ascitic fluid.

  • patients unable to give informed consent

  • non-resident patients

  • contraindication for an endoscopic examination

Contacts and Locations

Locations

Site City State Country Postal Code
1 Limmattal Spital Schlieren Zürich Switzerland 8952
2 Universitätsspital Bern Bern Switzerland 3010

Sponsors and Collaborators

  • Dr.med. Monica Rusticeanu
  • University Hospital Inselspital, Berne
  • University of Bern

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr.med. Monica Rusticeanu, Dr.med. M. Rusticeanu LÄ stv. Gastroenterologie und Hepatologie, Spital Limmattal Schlieren
ClinicalTrials.gov Identifier:
NCT03878563
Other Study ID Numbers:
  • 2017-00249
First Posted:
Mar 18, 2019
Last Update Posted:
Jul 13, 2020
Last Verified:
Jul 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dr.med. Monica Rusticeanu, Dr.med. M. Rusticeanu LÄ stv. Gastroenterologie und Hepatologie, Spital Limmattal Schlieren
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 13, 2020